Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Arrowhead Pharmaceuticals Inc

ARWR
Current price
23.17 USD +1.62 USD (+7.52%)
Last closed 21.2 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 489 199 360 USD
Yield for 12 month -27.18 %
Week
Month
Year
ARWR
21.11.2021 - 28.11.2021

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. Address: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105

Analytics

WallStreet Target Price

55.85 USD

P/E ratio

Dividend Yield

0.59 %

Current Year

+240 735 000 USD

Last Year

+243 231 000 USD

Current Quarter

+16 097 000 USD

Last Quarter

+15 825 000 USD

Current Year

+240 735 000 USD

Last Year

+243 231 000 USD

Current Quarter

+16 097 000 USD

Last Quarter

+15 825 000 USD

Key Figures ARWR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -193 490 000 USD
Operating Margin TTM -672.98 %
PE Ratio
Return On Assets TTM -17.58 %
PEG Ratio -1.32
Return On Equity TTM -59.33 %
Wall Street Target Price 55.85 USD
Revenue TTM 240 735 008 USD
Book Value 2.53 USD
Revenue Per Share TTM 2.26 USD
Dividend Share
Quarterly Revenue Growth YOY -49 %
Dividend Yield 0.59 %
Gross Profit TTM 243 231 000 USD
Earnings Share -1.92 USD
Diluted Eps TTM -1.92 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 9.8 %
Profit Margin -85.27 %

Dividend Analytics ARWR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARWR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 0.59 %
Last Split Factor 1:10
Payout Ratio
Last Split Date 17.11.2011
Dividend Date

Stock Valuation ARWR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 111.1111
Enterprise Value Revenue 9.1463
Price Sales TTM 10.34
Enterprise Value EBITDA -12.5337
Price Book MRQ 9.1776

Financials ARWR

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ARWR

For 52 weeks

20.67 USD 42.48 USD
50 Day MA 26.23 USD
Shares Short Prior Month 7 168 868
200 Day MA 30.47 USD
Short Ratio 7.67
Shares Short 7 876 562
Short Percent 8.77 %